Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BEYONDSPRING INC.

(BYSI)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
0.5963 USD   -1.05%
11/25Sector Update: Health Care Stocks Flat To Higher Premarket Friday
MT
11/25BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
11/24BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements, November 23, 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

09/13/2022 | 07:00am EST

BeyondSpring Inc. announced data from a poster presentation at the ESMO Congress 2022 being held September 9-13, 2022, in Paris, France. The poster includes a new analysis from the Phase 2/3 PROTECTIVE-1 (NCT03102606) and PROTECTIVE-2 (NCT03294577) trials. The data provides evidence of protection of bone marrow granulocyte-monocyte progenitor (GMP) stem cells within 24 hours after chemotherapy based on an evaluation of peripheral immature and mature neutrophil counts.

Peripheral blood counts for mature (segmented) and immature neutrophils, white blood cells (WBCs), red blood cells (RBCs) and platelets were obtained from LabCorp. The blood counts were analyzed before and 24 hours after chemo administration without (control; N=198) or with plinabulin (N=298). The absolute neutrophil count (ANC) with and without plinabulin was comparable at pre-dose C1D1 (p=0.96) but was significantly higher at 24 hours post-chemo dose with plinabulin vs.

control (p<0.0001). At 24 hours post-chemo dose, the mean ANC had increased by 3.2 x 109/L with plinabulin (p<0.0001) whereas the mean ANC had decreased by 0.55 x 109/L with the control (p=0.018) due to the myelosuppressive effect of TAC chemotherapy. Pre-dose (C1D1), the proportion of patients with a GMP-derived immature cell count value >0 was approximately 0 for both the plinabulin and control arms. At 24 hours post-chemo, the number of patients with an immature neutrophil count >0 had significantly increased with plinabulin but not with the control.

The proportion of patients with immature cells from all other WBCs and RBCs was approximately 0 at pre- or post-chemo dose with or without plinabulin. Plinabulin, BeyondSpring's lead asset, is a selective immunomodulating microtubule-binding agent, which is a potent antigen presenting cell (APC) inducer that is being developed as an anticancer agent. Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anti-cancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells and the second is a CIN prevention benefit.

Plinabulin has single agent anti-cancer activity in a number of cancers including small cell lung cancer (SCLC) and multiple myeloma (MM). Plinabulin also exerts early-onset of action in the prevention of chemotherapy-induced neutropenia (CIN) by boosting the number of hematopoietic stem/progenitor cells (HSPCs).


ę S&P Capital IQ 2022
All news about BEYONDSPRING INC.
11/25Sector Update: Health Care Stocks Flat To Higher Premarket Friday
MT
11/25BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
11/24BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements, November ..
AQ
11/23BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
AQ
09/19BeyondSpring Inc.(NasdaqCM:BYSI) dropped from S&P Global BMI ..
CI
09/13BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Mon..
AQ
09/13BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyt..
CI
08/31North American Morning Briefing: Stocks Look to -2-
DJ
08/29BeyondSpring Inc. Announces Board Appointments
CI
08/29BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease ..
AQ
More news
Analyst Recommendations on BEYONDSPRING INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -57,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,43x
Yield 2022 -
Capitalization 23,2 M 23,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 19,3x
Nbr of Employees 103
Free-Float 59,4%
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 0,60 $
Average target price 2,30 $
Spread / Average Target 286%
EPS Revisions
Managers and Directors
Lan Huang Chairman & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director, Chief Medical Officer, Executive VP-R&D
G. Kenneth Lloyd Chief Scientific Officer
Matthew Kirkby Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BEYONDSPRING INC.-86.84%23
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930